Aptargroup Q3 2026 earnings

ATR · 2026-10-29 17:08 AMC ET · 8-K on SEC · 10-Q on SEC

Revenue growth across segments, but margins compressed by unfavorable mix and a $58.0 million Russia deconsolidation charge.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$1.02B+6%+1%Ex. 99.1, income statement
EPS (GAAP)$0.51-73%-62%Ex. 99.1, income statement
EPS (adjusted)$1.52-6%+7%Ex. 99.1, income statement
Adj. EBITDA$217.2M-2%+2%Ex. 99.1, income statement
Adj. EBITDA margin21.3%-1.9 pp+0.6 ppEx. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Pharma$453.97M+2%44.5%Core sales +1% excluding emergency medicine destocking
Beauty$357.37M+9%35.1%Core sales +8%
Closures$207.78M+11%20.4%Core sales +11%

Margins and costs

  • Gross margin Not stated
  • Operating expenses $160.16M (+5% YoY)
  • One-offs in the quarter Russia deconsolidation loss $58.0M pre-tax ($60.4M after-tax); Other special items $3.1M
  • Effective tax rate 45.6% reported, 23.4% adjusted (prior year 17.1% reported, 20.8% adjusted)
  • Non-GAAP bridge Adds back restructuring, acquisition costs, purchase accounting, equity investment gains/losses, and Russia deconsolidation impacts

KPIs

MetricActualPrior quarterPrior yearChange
Free cash flow$98.6M$45.9M$114.3M+115%
Cash returned to shareholders$61M$81M$212M YTD—

Guidance

MetricGuidePrior guideChange
Adjusted EPS$1.39-$1.47$1.45-$1.53-0.06 to -0.06

What drove it

  • Revenue story Reported sales +6% to $1.02B; core sales +5%. Pharma +2% (core +1% ex. emergency medicine), Beauty +9% (core +8%), Closures +11% (core +11%).
  • EPS story Reported EPS down 73% YoY driven by Russia deconsolidation charge; Adjusted EPS down 6% YoY.
  • One-off check Russia deconsolidation loss $58.0M pre-tax ($60.4M after-tax) and related receivable reserves and legal costs.

The good

  • Broad-based revenue growth across all three segments
  • Adjusted EPS at the high end of guidance range
  • Free cash flow $98.6M

The bad

  • Adjusted EBITDA margin down 80 bps YoY due to unfavorable product mix
  • Beauty margin down 70 bps YoY due to unfavorable mix and North American challenges
  • Closures margin down 60 bps YoY due to dilutive pass-throughs

The ugly

  • Russia deconsolidation loss of $58.0M pre-tax ($60.4M after-tax) and $0.94 per diluted share

Open questions

  • Impact of unfavorable product mix on margins and whether it will persist
  • Specifics of ongoing challenges in North American operations
  • Timing of the abatement of emergency medicine destocking headwind
Full release

Earnings: ATR — filed 2026-10-29

Aptargroup, Inc. (ATR) · Form 8-K, Item 2.02 · Filed · SEC filing

Aptar Reports Third Quarter 2026 Results

Crystal Lake, Illinois, October 29, 2026 -- AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today reported the following third quarter results for the period ended September 30, 2026, as compared to the corresponding period of the last fiscal year.

Third Quarter 2026 Highlights

(Compared to the prior year quarter; see Non-GAAP section for full definitions; see reconciliation for Non-GAAP measures)

• Reported sales increased 6% and core sales increased 5%

• Reported net income was $33 million and reported earnings per share were $0.51, impacted by deconsolidation of the Russian subsidiary

• Adjusted earnings per share were $1.52, at the higher end of the guidance range, compared to $1.62 in the prior year period at comparable exchange rates

• Adjusted EBITDA margin was 21.3%, compared to 23.2% in the prior year quarter

• Returned $61 million in the quarter and $272 million year-to-date to shareholders through share repurchases and dividends

• Subsequent to the quarter, the Board of Directors approved an increase in the quarterly cash dividend from $0.48 to $0.50

“We delivered broad-based revenue growth across all three segments. Pharma delivered impressive growth in central nervous system therapies, pulmonary, injectables and consumer healthcare, while maintaining profitability at the high end of our long-term target range. Our Pharma pipeline remains strong, with continued focus on building the pipeline and converting opportunities into future growth. New technologies and development programs are expanding the role we can play with customers across the drug development cycle. Beauty and Closures also delivered strong top-line growth, including double-digit core sales growth in Closures, where innovation in beverage dispensing continues to gain momentum. As I begin my tenure as CEO, our direction is clear: deepen our position with customers, accelerate innovation, execute with greater consistency and allocate capital thoughtfully. These priorities will guide how we drive profitable growth and create long-term value for Aptar and our shareholders,” said Gael Touya, Aptar President and CEO.

Third Quarter Results

For the quarter ended September 30, 2026, reported sales increased 6% to $1.02 billion compared to $961 million in the prior year and core sales increased 5% compared to the prior year period.

Financial statements

Income Statement

Three Months Ended September 30, — Consolidated Statements of Income

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net Sales1,019,119961,1313,028,4952,814,445
Cost of Sales (exclusive of depreciation and amortization shown below)646,196598,0461,938,1461,747,931
Selling, Research & Development and Administrative160,164148,760485,501455,176
Depreciation and Amortization75,54475,234230,910210,785
Restructuring Initiatives2,2082,1684,7135,789
Operating Income135,007136,923369,225394,764
Other Income (Expense):
Interest Expense-15,790-13,532-48,733-35,733
Interest Income1,9302,4008,3597,094
Net Investment (Loss) Gain-1,011-161-1,160845
Loss on Russia Deconsolidation-58,020-58,020
Equity in Results of Affiliates1,1061,7473,2246,142
Gain from Remeasurement of Equity Method Investment26,51826,518
Miscellaneous Expense, net-2,889232-3,744226
Income before Income Taxes60,333154,127269,151399,856
Provision for Income Taxes27,51126,29575,55281,629
Net Income32,822127,832193,599318,227
Net (Income) Loss Attributable to Noncontrolling Interests-226-47-38276
Net Loss (Income) Attributable to Redeemable Noncontrolling Interests6142-368142
Net Income Attributable to AptarGroup, Inc.32,602127,927192,849318,445
Net Income Attributable to AptarGroup, Inc. per Common Share:
Basic0.511.953.034.83
Diluted0.511.9234.75
Average Numbers of Shares Outstanding:
Basic63,52365,70963,73365,989
Diluted64,14766,63064,37367,043

Income Statement

Three Months Ended September 30, 2026 — ($ In Thousands)

Three Months Ended September 30, 2026 – ConsolidatedThree Months Ended September 30, 2026 – PharmaThree Months Ended September 30, 2026 – BeautyThree Months Ended September 30, 2026 – ClosuresThree Months Ended September 30, 2026 – Corporate & OtherThree Months Ended September 30, 2026 – Net Interest
Net Sales1,019,119453,970357,372207,777$—
Reported net income32,822
Reported income taxes27,511
Reported income before income taxes60,333122,5895,363-22,985-30,774-13,860
Adjustments:
Restructuring initiatives2,2084061,827-25
Net investment loss1,0111,011
Russia deconsolidation impact61,1613,1379,55540,6267,843
Other special items3,0953,095
Adjusted earnings before income taxes127,808129,22716,74517,616-21,920-13,860
Interest expense15,79015,790
Interest income-1,930-1,930
Adjusted earnings before net interest and taxes (Adjusted EBIT)141,668129,22716,74517,616-21,920
Depreciation and amortization75,54435,91123,96514,5611,107
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)217,212165,13840,71032,177-20,813$—
Reported net income margins (Reported net income / Reported Net Sales)3.2%
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)21.3%36.411.415.5

Income Statement

Three Months Ended September 30, 2025 — ($ In Thousands)

Three Months Ended September 30, 2025 – ConsolidatedThree Months Ended September 30, 2025 – PharmaThree Months Ended September 30, 2025 – BeautyThree Months Ended September 30, 2025 – ClosuresThree Months Ended September 30, 2025 – Corporate & OtherThree Months Ended September 30, 2025 – Net Interest
Net Sales961,131445,410327,768187,953$—
Reported net income127,832
Reported income taxes26,295
Reported income before income taxes154,127124,75940,07314,714-14,287-11,132
Adjustments:
Restructuring initiatives2,168919550702-3
Net investment loss161161
Gain from remeasurement of equity method investment-26,518-26,518
Transaction costs related to acquisitions748584164
Purchase accounting adjustments related to acquisitions and investments1,1481,148
Other special items4,4004,400
Adjusted earnings before income taxes136,234130,66215,41715,416-14,129-11,132
Interest expense13,53213,532
Interest income-2,400-2,400
Adjusted earnings before net interest and taxes (Adjusted EBIT)147,366130,66215,41715,416-14,129
Depreciation and amortization75,23435,10724,33214,921874
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)222,600165,76939,74930,337-13,255$—
Reported net income margins (Reported net income / Reported Net Sales)13.3

Income Statement

Nine Months Ended September 30, 2026 — ($ In Thousands)

Nine Months Ended September 30, 2026 – ConsolidatedNine Months Ended September 30, 2026 – PharmaNine Months Ended September 30, 2026 – BeautyNine Months Ended September 30, 2026 – ClosuresNine Months Ended September 30, 2026 – Corporate & OtherNine Months Ended September 30, 2026 – Net Interest
Net Sales3,028,4951,350,6971,088,461589,337$—
Reported net income193,599
Reported income taxes75,552
Reported income before income taxes269,151339,84338,3961,434-70,148-40,374
Adjustments:
Restructuring initiatives4,7133454,545311-488
Net investment loss1,1601,160
Realized gain on investments included in net investment loss above8888
Russia deconsolidation impact61,1613,1379,55540,6267,843
Transaction costs related to acquisitions8383
Purchase accounting adjustments related to acquisitions and investments145145
Other special items10,89910,899
Adjusted earnings before income taxes347,400354,45252,49642,371-61,545-40,374
Interest expense48,73348,733
Interest income-8,359-8,359
Adjusted earnings before net interest and taxes (Adjusted EBIT)387,774354,45252,49642,371-61,545
Depreciation and amortization230,910110,81473,43843,3123,346
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)618,684465,266125,93485,683-58,199$—
Reported net income margins (Reported net income / Reported Net Sales)6.4
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)20.434.411.614.5

Income Statement

Nine Months Ended September 30, 2025 — ($ In Thousands)

Nine Months Ended September 30, 2025 – ConsolidatedNine Months Ended September 30, 2025 – PharmaNine Months Ended September 30, 2025 – BeautyNine Months Ended September 30, 2025 – ClosuresNine Months Ended September 30, 2025 – Corporate & OtherNine Months Ended September 30, 2025 – Net Interest
Net Sales2,814,4451,297,466968,324548,655
Reported net income318,227
Reported income taxes81,629
Reported income before income taxes399,856358,46581,38244,593-55,945-28,639
Adjustments:
Restructuring initiatives5,7891,1771,5712,94497
Net investment gain-845-845
Gain from remeasurement of equity method investment-26,518-26,518
Transaction costs related to acquisitions1,092584508
Purchase accounting adjustments related to acquisitions and investments1,1481,148
Other special items4,4004,400
Adjusted earnings before income taxes384,922364,62658,09147,537-56,693-28,639
Interest expense35,73335,733
Interest income-7,094-7,094
Adjusted earnings before net interest and taxes (Adjusted EBIT)413,561364,62658,09147,537-56,693
Depreciation and amortization210,785100,42465,86941,9432,549
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA)624,346465,050123,96089,480-54,144
Reported net income margins (Reported net income / Reported Net Sales)11.3
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales)22.235.812.816.3

Income Statement

Three Months Ended September 30, — (In Thousands, Except Per Share Data)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Income before Income Taxes60,333154,127269,151399,856
Adjustments:
Restructuring initiatives2,2082,1684,7135,789
Net investment loss (gain)1,0111611,160-845
Realized gain on investments included in net investment loss (gain) above88
Russia deconsolidation impact61,16161,161
Gain from remeasurement of equity method investment-26,518-26,518
Transaction costs related to acquisitions748831,092
Purchase accounting adjustments related to acquisitions and investments1,1481451,148
Other special items3,0954,40010,8994,400
Foreign currency effects (1)-3719,866
Adjusted Earnings before Income Taxes127,808135,863347,400394,788
Provision for Income Taxes27,51126,29575,55281,629
Restructuring initiatives5575611,2401,488
Net investment loss (gain)24739284-207
Realized gain on investments included in net investment loss (gain) above22
Russia deconsolidation impact785785
Transaction costs related to acquisitions18220268
Purchase accounting adjustments related to acquisitions and investments17249172
Other special items7881,0782,8151,078
Foreign currency effects (1)-632,014

Income Statement

Three Months Ending December 31, — (In Thousands, Except Per Share Data)

Three Months Ending December 31, – 2025
Income before Income Taxes91,522
Adjustments:
Restructuring initiatives4,048
Curtailment gain related to restructuring initiatives-115
Net investment loss1,328
Transaction costs related to acquisitions368
Purchase accounting adjustments related to acquisitions and investments645
Other special items3,960
Foreign currency effects (1)-2,485
Adjusted Earnings before Income Taxes99,271
Provision for Income Taxes17,252
Restructuring initiatives1,015
Curtailment gain related to restructuring initiatives-30
Net investment loss325
Transaction costs related to acquisitions125
Purchase accounting adjustments related to acquisitions and investments110
Other special items970
Foreign currency effects (1)-468
Adjusted Provision for Income Taxes19,299
Net Loss Attributable to Noncontrolling Interests130
Net Income Attributable to Redeemable Noncontrolling Interests-56
Net Income Attributable to AptarGroup, Inc.74,344
Restructuring initiatives3,033
Curtailment gain related to restructuring initiatives-85
Net investment loss1,003
Transaction costs related to acquisitions243
Purchase accounting adjustments related to acquisitions and investments535
Other special items2,990
Foreign currency effects (1)-2,017
Adjusted Net Income Attributable to AptarGroup, Inc.80,046
Average Number of Diluted Shares Outstanding65,796

Balance Sheet

September 30, 2026 — Consolidated Balance Sheets

September 30, 2026December 31, 2025
ASSETS
Cash and Equivalents204,176402,424
Short-term Investments8,1217,109
Accounts and Notes Receivable, Net883,939803,830
Inventories582,605537,845
Prepaid and Other157,950142,354
Total Current Assets1,836,7911,893,562
Property, Plant and Equipment, Net1,635,5301,676,479
Goodwill1,067,1521,077,898
Other Assets572,153604,780
Total Assets5,111,6265,252,719
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY
Short-Term Obligations350,681343,531
Accounts Payable, Accrued and Other Liabilities872,133822,913
Total Current Liabilities1,222,8141,166,444
Long-Term Obligations1,024,7351,139,433
Deferred Liabilities and Other202,894234,617
Total Liabilities2,450,4432,540,494
Redeemable Noncontrolling Interests28,04826,244
Total Mezzanine Equity28,04826,244
AptarGroup, Inc. Stockholders' Equity2,614,3242,668,096
Noncontrolling Interests in Subsidiaries18,81117,885
Total Stockholders' Equity2,633,1352,685,981
Total Liabilities, Mezzanine Equity and Stockholders' Equity5,111,6265,252,719

Cash Flow

Nine Months Ended September 30, — Consolidated Statement of Cash Flows

20262025
Net income193,599318,227
Adjustments to reconcile net income to net cash provided by operations:
Depreciation198,044177,412
Amortization32,86633,373
Stock-based compensation33,04336,772
Provision for CECL4,374516
Loss (gain) on disposition of fixed assets48477
Loss on Russia deconsolidation58,020

Cash Flow

Three Months Ended September 30, — (In Thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net Cash Provided by Operations167,598177,606389,778386,306
Capital Expenditures-69,006-63,313-191,965-183,600
Proceeds from Government Grants3,308
Free Cash Flow98,592114,293197,813206,014

(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates.¹

Pharma’s reported sales increased 2% compared to the prior year period and c ore sales increased

1%. Adjusting for emergency medicine destocking,

Pharma delivered

8% core sales growth in the quarter. Performance was supported by continued growth across a number of end markets, including central nervous system and pulmonary therapies, nasal decongestants, eye care and dermal drug delivery solutions, and demand related to biologics, vaccines and GLP-1 therapies. These growth drivers were partially offset by the anticipated reduction in emergency medicine sales. Pharma delivered adjusted EBITDA margin of 36.4% a decline of 80 basis points, remaining above our long-term target despite a short-term unfavorable product mix related to destocking. Royalties and productivity improvements continued to positively impact margins.

Beauty’s reported sales increased 9% when compared to the prior year period, with core sales growth of 8%.

There was increased demand for prestige fragrance dispensing, color cosmetics, as well as hair care applications, and pass throughs of higher input costs also contributed positively. Adjusted EBITDA margin was 11.4%, a decline of 70 basis points, including unfavorable mix and ongoing challenges in North American operations.

Closures’ reported sales rose 11% from the prior year period, with c ore sales growth of 11%. Beverage and food sales grew significantly, led by strong demand for bottled water and concentrates, continued momentum from our latest beverage dispensing closure innovation, as well as strong condiment sales. Pass throughs of higher input costs contributed positively to core sales growth, however, the dilutive impact drove the decline of 60 basis points in Adjusted EBITDA margin to 15.5%.

During the third quarter, Aptar deconsolidated its Russian subsidiary following a governmental decree placing the subsidiary under external administration and the resulting loss of control. Aptar recorded a $58.0 million loss on deconsolidation which included approximately $30.0 million of cash held by the subsidiary. The combined impact was $61.2 million before tax, including approximately $2.6 million of related receivable reserves and $0.5 million of related legal costs; and $60.4 million after tax, or $0.94 per diluted share.

Reported third quarter earnings per share were $0.51 compared to $1.92 reported a year ago. Adjusted earnings per share were $1.52, compared to the prior year period’s adjusted earnings per share of $1.62, including comparable exchange rates. The third quarter reported effective tax rate was 45.6%, reflecting the non-deductible tax impact of the deconsolidation of the Russian subsidiary. The adjusted effective tax rate was 23.4%, compared to the prior year period’s reported effective tax rate of 17.1% and adjusted effective tax rate of 20.8%.

Nine Months Year-to-Date Results

For the nine months ended September 30, 2026, reported sales increased 8% to $3.03 billion compared to $2.81 billion in the prior year and core sales increased 2%.

(1) - Currency effects are approximated by translating last year's amounts at this year's foreign exchange rates.

For the nine months ended September 30, 2026, Aptar’s reported earnings per share were $3.00, a decrease of 37%, which was also impacted by the deconsolidation of the Russian subsidiary, compared to $4.75 reported a year ag... (truncatest nine months of 2026, adj usted earnings per share were $4.13 and decreased 10% from prior year adjusted earnings per share of $4.60, including comparable exchange rates. The current year had a reported effective tax rate of 28.1% and an adjusted effective tax rate of 23.2% compared to the prior year reported and adjusted effective tax rates of 20.4% and 21.9%, respectively.²

Outlook

Regarding Aptar’s outlook, Touya stated,

“We expect Aptar to finish the year strong, supported by continued Pharma growth, particularly in consumer healthcare and injectables and without the headwind from emergency medicine destocking. Our Pharma pipeline remains strong, with new technologies and development programs expanding our reach across therapeutic areas and advancing opportunities for future growth. Closures continues its great momentum, with innovation helping drive increased demand, particularly for our beverage technologies. In Beauty, we remain focused on improving our long-term North American trajectory, while we continue to see pockets of healthy demand in areas, such as prestige fragrance, globally.”

Aptar currently expects adjusted earnings per share for the fourth quarter of 2026 to be in the range of $1.39 to $1.47. This guidance assumes an effective tax rate range of 17.5% to 19.5%. The earnings per share guidance range is assuming a

1.12

Euro to USD exchange rate.

Cash Dividends and Share Repurchases

During the third quarter, Aptar repurchased approximately 234 thousand shares for $30 million. Aptar may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions. As previously announced, Aptar’s Board of Directors approved a quarterly cash dividend of $0.50 per share. The payment date is December 3, 2026, to stockholders of record as of November 12, 2026.

Open Conference Call

There will be a conference call held on Friday, October 30, 2026 at 8:00 a.m. Central Time to discuss the company’s third quarter results for 2026. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investor Relations website at investors.aptar.com. Replay of the conference call can also be accessed for a limited time on the Investor Relations page of the website.

About Aptar

Aptar is a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at http://www.aptar.com.³

Presentation of Non-GAAP Information

This press release refers to certain non-GAAP financial measures, including current year adjusted earnings per share and adjusted EBITDA, which exclude the impact of restructuring initiatives, acquisition-related costs, certain purchase accounting adjustments related to acquisitions and investments, gains from remeasurement of equity method investments and net unrealized investment gains and losses related to observable market price changes on equity securities, Russia deconsolidation impacts, and other special items. Core sales and adjusted earnings per share also neutralize the impact of foreign currency translation effects when comparing current results to the prior year. Core sales also exclude material acquisitions and, for the three and nine months ended September 30, 2026, the Russian subsidiary’s net sales from both periods. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, restructuring initiatives, acquisition-related costs, purchase accounting adjustments related to acquisitions and investments, gains from remeasurement of equity method investments, net unrealized investment gains and losses related to observable market price changes on equity securities, Russia deconsolidation impacts, and other special items. Russia deconsolidation impacts comprise the loss on deconsolidation of our Russian subsidiary and related receivable reserves and legal costs described above, which we exclude because they resulted from a government action rather than from the operations of our businesses and therefore do not reflect the underlying performance of our remaining operations. For the three and nine months ended

September 30, 2026 and 2025,

“Other special items” include costs incurred related to non-ordinary-cour se litigation, specifically: lawsuits between Aptar and ARS Pharmaceuticals, Inc., involving Aptar’s claims of trade-secret misappropriation and contractual breaches and ARS’s lawsuit against Aptar under U.S. antitrust laws; and patent infringement actions filed by Nemera La Verpillière SAS in Germany and France relating to certain of Aptar’s ophthalmic products.... (truncated)nagement when making financial and operational decisions. Free cash flow is calculated as cash provided by operating activities less capital expenditures plus proceeds from government grants related to capital expenditures. We use free cash flow to measure cash flow generated by operations that is available for dividends, share repurchases, acquisitions and debt repayment. We believe that it is meaningful to investors in evaluating our financial performance and measuring our ability to generate cash internally to fund our initiatives. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial results but should be read in conjunction with the unaudited condensed consolidated statements of income and other information presented herein. A reconciliation of non-GAAP financial measures to the most directly comparable GAAP measures is included in the accompanying tables. Our outlook is provided on a non-GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates and changes in the fair value of equity investments, or reliably predicted because they are not part of our routine activities, such as restructuring initiatives, acquisition-related costs and other special items.⁴

This press release contains forward-looking statements, including certain statements set forth under the “Outlook” section of this press release. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential,” “continues” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results or other events may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: geopolitical conflicts worldwide and the resulting indirect impact on demand from our customers selling their products into these countries and certain supply chain disruptions; as well as governmental actions affecting our foreign operations and assets, including the loss of control over, and our ability to recover value from, our Russian operations; cybersecurity threats against our systems and/or service providers that could impact our networks and reporting systems; the availability of raw materials and components (particularly from sole sourced suppliers for some of our Pharma solutions) as well as the financial viability of these suppliers; our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights; the outcome of any legal proceeding that has been or may be instituted against us and others; our ability to keep pace with competition and technological advances, including in connection with the shifting of Pharma origination to less regulated markets; lower demand and asset utilization due to an economic recession either globally or in key markets we operate within; economic conditions worldwide, including inflationary conditions and potential deflationary conditions in other regions we rely on for growth; significant tariffs and other restrictions on foreign imports imposed by the U.S. and related countermeasures taken by impacted foreign countries; our ability to successfully implement facility expansions and new facility projects; fluctuations in the cost of materials, components, transportation cost as a result of supply chain disruptions and labor shortages, and other input costs; significant fluctuations in foreign currency exchange rates or our effective tax rate and cash flow; the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate; financial conditions of customers and suppliers; consolidations within our customer or supplier bases; changes in customer and/or consumer spending levels; loss of one or more key products or accounts; our ability to offset inflationary impacts with cost containment, productivity initiatives and price increases; changes in capital availability or cost, interest rate volatility; loss of royalty revenue due to contract expirations; volatility of global credit markets; our ability to identify potential new acquisitions and to successfully acquire and integrate such operations, including the successful integration of the businesses we have acquired; our ability to build out acquired businesses and integrate the product/service offerings of the acquired entities into our existing product/service portfolio; direct or indirect consequences of acts of war, terrorism or social unrest; the impact of natural disasters and other weather-related occurrences; fiscal and monetary policies and other regulations; changes, difficulties or failures in complying with government regulation, including FDA or similar foreign governmental authorities; changing regulations or market conditions regarding environmental sustainability; our ability to retain key members of management and manage labor costs; work stoppages due to labor disputes; our ability to meet future cash flow estimates to support our goodwill impairment testing; the demand for existing and new products; the success of our customers’ products, particularly in the pharmaceutical industry; our ability to manage worldwide customer launches of complex technical products, particularly in developing markets; difficulties in product development and uncertainties related to the timing or outcome of product development; significant product liability claims; and other risks associated with our operations. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-K and Form 10-Qs. Readers are cautioned not to place undue reliance on forward-looking statements. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contacts

Investor Relations Contact

:

Mary Skafidas mary.skafidas@aptar.com

815-479-5530

Media Contact:

Katie Reardon katie.reardon@aptar.com

815-479-5671⁵

AptarGroup, Inc.

Condensed Consolidated Financial Statements (Unaudited)

(In Thousands, Except Per Share Data)

Consolidated Statements of Income⁶

AptarGroup, Inc.

Condensed Consolidated Financial Statements (Unaudited)

(continued)

($ In Thousands)

Consolidated Balance Sheets⁷

AptarGroup, Inc.

Condensed Consolidated Financial Statements (Unaudited)

(continued)

($ In Thousands)

Consolidated Statement of Cash Flows⁸

AptarGroup, Inc.

Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)

($ In Thousands)⁹

AptarGroup, Inc.

Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)

($ In Thousands)¹⁰

AptarGroup, Inc.

Reconciliation of Adjusted EBIT and Adjusted EBITDA to Net Income (Unaudited)

($ In Thousands)¹¹

AptarGroup, Inc.

Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)

(In Thousands, Except Per Share Data)¹²

(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current period foreign currency exchange rates.¹³

AptarGroup, Inc.

Reconciliation of Free Cash Flow to Net Cash Provided by Operations (Unaudited)

(In Thousands)¹⁴

AptarGroup, Inc.

Reconciliation of Adjusted Earnings Per Diluted Share (Unaudited)

(In Thousands, Except Per Share Data)¹⁵

(1) Foreign currency effects are approximations of the adjustment necessary to state the prior year earnings and earnings per share using current spot rates for all applicable foreign currency exchange rates.

(2) AptarGroup’s expected adjusted earnings per share range for the fourth quarter of 2026, see non-GAAP section for full definition, is based on an effective tax rate range of 17.5% to 19.5%. This tax rate range compares to our fourth quarter of 2025 effective tax rate of 18.9% on reported earnings per share and 19.4% on adjusted earnings per share.¹⁶

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Aptargroup earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.